Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer
The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent head and neck cancer
Head and Neck Cancer
DRUG: Paclitaxel
Response rate according to the WHO criteria, Every 4 weeks
Duration of response according to the WHO criteria, Every 4 weeks|Response rate according to RECIST criteria, Every 4 weeks
The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent head and neck cancer